Onyango Isaac G, Bennett James P, Stokin Gorazd B
Center for Translational Medicine, International Clinical Research Centre (ICRC), St. Anne's University Hospital, Brno, Czech Republic.
Neurodegeneration Therapeutics, 3050A Berkmar Drive, Charlottesville, VA, USA.
Neural Regen Res. 2021 Aug;16(8):1467-1482. doi: 10.4103/1673-5374.303007.
Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are a heterogeneous group of debilitating disorders with multifactorial etiologies and pathogeneses that manifest distinct molecular mechanisms and clinical manifestations with abnormal protein dynamics and impaired bioenergetics. Mitochondrial dysfunction is emerging as an important feature in the etiopathogenesis of these age-related neurodegenerative diseases. The prevalence and incidence of these diseases is on the rise with the increasing global population and average lifespan. Although many therapeutic approaches have been tested, there are currently no effective treatment routes for the prevention or cure of these diseases. We present the current status of our knowledge and understanding of the involvement of mitochondrial dysfunction in these diseases and highlight recent advances in novel therapeutic strategies targeting neuronal bioenergetics as potential approach for treating these diseases.
神经退行性疾病，如阿尔茨海默病、帕金森病、亨廷顿舞蹈病和肌萎缩侧索硬化症，是一组异质性的衰弱性疾病，其病因和发病机制具有多因素性，表现出不同的分子机制和临床表现，伴有异常的蛋白质动态变化和生物能量学受损。线粒体功能障碍正在成为这些与年龄相关的神经退行性疾病病因发病机制中的一个重要特征。随着全球人口和平均寿命的增加，这些疾病的患病率和发病率正在上升。尽管已经测试了许多治疗方法，但目前尚无预防或治愈这些疾病的有效治疗途径。我们介绍了目前对线粒体功能障碍在这些疾病中的参与情况的认识和理解，并强调了针对神经元生物能量学的新型治疗策略的最新进展，作为治疗这些疾病的潜在方法。
